Details
The second of EASL's live webinars on COVID-19 addresses the topic of vaccination in patients with liver disease. This was chaired by Professor Ulrich Spengler and Professor Verena Keitel, who were joined by Dr Thomas Marjot, Professor Julian Schulze-zur-Wiesch, Professor Dr Miriam Sturkenboom and Professor Rifaat Safadi. Dr Marjot presented on the prioritizing liver disease patients for COVID-19 vaccination followed by an Overview of COVID-19 vaccines available in Europe presented by Professor Schulze-zur-Wiesch. Professor Sturkenboom presented the Benefit/risk of COVID-19 vaccinations: current knowledge and specific populations before Professor Safadi closed with the First practical experiences with COVID-19 vaccinations in Israeli patients with liver disease. A fascinating Q&A session after the main presentations covered a range of topics including how to monitor vaccine efficacy in liver disease patients, what needs to be done in countries with limited supply, whether COVID-19 vaccines can be combined with others and recommendations for specific patient profiles.
Target Audience
- Hepatologists, gastroenterologists
- General practitioners
- Health care professionals
- Clinical scientists
- Basic scientists
Learning Objectives
- Learn about the relative risk for severe COVID-19 in patients with chronic liver diseases (cirrhosis, metabolic and autoimmune liver disease, liver transplantation) as compared to other high-risk populations
- Learn about the efficacy and safety of current COVID-19 vaccines (mRNA vaccines, vector vaccines), their contraindications and limitations in patients with liver diseases
- Learn about the scientific rationale for currently recommended vaccination strategies concerning patients with liver diseases
- Learn about the first outcome data of population-based vaccination in patients with and without liver diseases
Title |
Welcome & Introduction Ulrich Spengler, University of Bonn, Germany Verena Keitel, University Hospital of Düsseldorf, Germany |
Defining liver patients in urgent need of a COVID-19 vaccine for priorisation Thomas Marjot, University of Oxford, United Kingdom |
Overview of the COVID-19 vaccines available in Europe Julian Schulze-zur-Wiesch, University Medical Center Hamburg-Eppendorf, Germany |
Benefit/Risk of COVID-19 vaccinations: Current knowledge and how it translates to specific populations Miriam Sturkenboom, Julius Center Research Program Cardiovascular Epidemiology, Netherlands |
First practical experiences with COVID-19 vaccination in Israeli patients with liver disease Rifaat Safadi, Hadassah Medical Centers of the Hebrew, University Jerusalem, Israel |
Discussion and Q&A All |